J&J and Laurus Settle Patent Swimsuit on Opsumit Hypertension Drug
Health Law & Business News
Jan. 25, 2021, 3:34 PM
J&J’s Actelion unit had claimed that a generic version of pulmonary hypertension drug Opsumit jointly proposed by Laurus and closely held PharmaQ infringes a patent.
- Laurus conceded the patent’s validity and that its copycat would infringe, and Laurus agreed to be blocked from making copies until the patent has expired “unless otherwise specifically authorized” by Actelion, according to consent judgment approved Friday in federal court in Wilmington, Delaware
- Judgment mentions license agreement but provides no further details
- Opsumit had U.S. sales of $729 million during the first nine months of 2020, up from $581 million during the same period…
© 2021 The Bureau of National Affairs, Inc.
All Rights Reserved